Profitable companies and non-Profitable Biotech companies (rising stars) have developed innovative drugs for treatment of chronic and non chronic diseases. In the next five years the distinction between mature biotech companies and large global pharma is likely to disappear as investment in R&D and acquisition start delivering and Market Cap match the large global pharma. Dividend and consolidation could be the future drivers and continue to attract long term investors. Optimism prevails around the future of this sector as a whole which was reflected in the unprecedented rally in shares in 2012.
This trend continued in the next five years driven by launch of Innovative drugs catering to unmet needs in Alzheimer’s, HCV, osteoporosis, RA, Psoriasis, MS, Dyslipidemia, Cystic fibrosis, Cancer and orphan diseases. Drug approvals and label expansion of existing portfolio of launched drugs and data from late stage pipeline drugs should maintain the growth momentum and investors interest.
The early part of the previous decade (2010-20) was spent recovering from the big acquisitions made by this sector but followed by the exercising of some restrain for similar large acquisitions as investors wanted to see the returns reflected in the top-line and EPS. However in- licensing of early or mid stage compounds or small acquisitions continued since the Rising Stars kept throwing the bait by taking risks and innovate using novel technology platforms or validating novel targets for treating diseases.
Patent expiry impact was also modest as majority had “not so easy to copy” biologics and other drugs in their portfolio. They, however were not complacent and were not leaving any stones unturned to meet the challenges as well as exploring emerging market opportunities with local partners. Favorable regulatory environment finally saw biosimilar mAbs entry in regulated markets The optimism of biosimilar players is reflected in the maturing pipeline. Para IV Filing from other generic players continues to pour leaving room for surprises and volatility.
Moving forward the sector should see a strategic rise of the digital mindset and further adoption of transformative and augumentative technologies. While mergers & acquisitions can still expect a sharper focus despite being more traditional, external innovation should result in a meaningful shift in culture through innovative and creative partnerships with both new entrants and less traditional companies.
There will be an increasing demand for even more transparency and disclosure and a need for real relationship-driven partnerships will encroach across all sector stakeholders including regulators, patients, advocacy groups and also to outsourcing players critical to the supply chain. Data will be a dominating force behind new revenue models and crucial to understanding and delivering an exceptional patient experience. Pricing will continue to exert much pressure, increasing access to drugs, growth of gene and cell therapies, and uncertain trade policies will further change the dynamics of the market.
Industry News
- Age, Education and Treatment Choices Shape Prostate Cancer Survival in Landmark Brazilian Study of 10,556 Menby Bioengineer on September 13, 2026 at 3:16 am
Prostate cancer remains one of the most commonly diagnosed malignancies in the world, and a new large-scale analysis from Brazil is shedding fresh light on which patients are most at risk of dying from the disease. Researchers followed more than ten thousand men treated within the oncology care network of the southeastern state of Espírito
- Gut Oxygen Sensor Shields Against Obesity but Adds Nothing to Weight-Loss Surgeryby Bioengineer on September 13, 2026 at 3:15 am
Hypoxia-inducible factor 1 alpha, or HIF1α, has long been celebrated as the master switch that allows cells to sense and survive low-oxygen conditions, a discovery that earned the 2019 Nobel Prize in Physiology or Medicine. In the intestine, this transcription factor is far more than a molecular oxygen alarm. It orchestrates the barrier function of
- Phosphate-Tuned Acidity Turns Niobium Catalyst Into a CO2-to-Fuel Powerhouseby Bioengineer on September 13, 2026 at 3:14 am
Scientists in Brazil have found a remarkably simple way to supercharge a catalyst that converts carbon dioxide into useful chemicals: give its surface a phosphoric acid bath. In research published in Catalysis Letters, a team led by Elson Oliveira, Jean Castro da Cruz, Washington Luiz Esteves Magalhaes and Caue Ribeiro demonstrated that treating niobium pentoxide
- Seaweed-Derived Coating Matches Heparin at Keeping Blood From Clottingby Bioengineer on September 13, 2026 at 3:13 am
A coating built from red seaweed could soon replace one of medicine’s most indispensable yet most fragile ingredients. In a study published in Discover Biotechnology, researchers at Colorado State University, the Federal University of Rio Grande do Norte, the University of Wyoming and George Mason University demonstrated that carboxymethyl kappa-carrageenan, a modified polysaccharide extracted from
- Refactoring Trick Supercharges AI Detection of Bad Code, Study Findsby Bioengineer on September 13, 2026 at 3:12 am
Software has an odor problem, at least metaphorically. So-called code smells—structural weaknesses such as oversized classes, duplicated logic, and tangled methods—are early warning signs that a codebase is rotting from within, and they cost the software industry billions in maintenance and rework every year. Now a research team from Fatih Sultan Mehmet Vakif University and
- From Fat Hen to Field Guide: First Full BBCH Growth-Stage Map Reveals How Winter and Summer Lambsquarters Live Two Different Livesby Bioengineer on September 13, 2026 at 3:11 am
Few plants embody the paradox of modern agriculture quite like Chenopodium album L., the ubiquitous annual known to farmers as fat-hen or lambsquarters and to foragers across South Asia as a nutrient-rich leafy vegetable. Now, researchers in India have delivered what the species has long lacked: a complete, standardized phenological blueprint documenting its entire life
- Copper and Iron Cell Death Pathways Offer a New Two-Front Attack on Liver Cancerby Bioengineer on September 13, 2026 at 3:09 am
Hepatocellular carcinoma, the most common form of primary liver cancer, remains one of the world’s most lethal malignancies, and its treatment options have changed surprisingly little over the past two decades. Now, a review published in Medical Oncology argues that the disease may have an Achilles heel hiding in an unexpected place: the way its
- mRNA flu vaccine sustains germinal centers to broaden antibody responses, study findsby Bioengineer on September 13, 2026 at 3:08 am
Influenza has long been one of medicine’s most stubborn adversaries, not because the virus cannot be countered, but because it refuses to stand still. Through continual antigenic drift, the hemagglutinin and neuraminidase proteins on the viral surface accumulate mutations that erode the protective power of antibodies generated by previous infections and vaccinations. This molecular shapeshifting
- Recycling PFAS Waste Into Silver Fluoride for Cleaner Chemistryby Bioengineer on September 13, 2026 at 3:07 am
Fluorinated waste streams have long been among the most stubborn environmental problems of the industrial age, and few sources illustrate the challenge better than aqueous film-forming foam, the firefighting agent that has contaminated soil and groundwater around airports, military bases and refineries for decades. The perfluoroalkyl and polyfluoroalkyl substances it contains, collectively known as PFAS,
- A Traditional Medicinal Root Reveals Antioxidant and Anti-Inflammatory Potential in New Studyby Bioengineer on September 13, 2026 at 3:05 am
A root long used in traditional East Asian medicine is now giving up its chemical secrets to modern analytical science. Researchers at Kyungpook National University, working with a collaborator at the University of California, Davis, have carried out an integrated investigation of the lipophilic fraction of Liriope platyphylla root, a plant known in Korea and
- New AI Model Spots Radar Jamming Even When Signals Are Buried in Noiseby Bioengineer on September 13, 2026 at 3:05 am
Radar systems are the invisible guardians of modern aviation, shipping, and defense, but they operate in an increasingly hostile electromagnetic environment. Adversaries deliberately flood the spectrum with jamming signals designed to blind radars, confuse their receivers, and mask real targets. Knowing exactly what kind of jamming is attacking a radar is the first step in
- Microbes and nanomaterials offer big yield gains for Africa’s stressed soilsby Bioengineer on September 13, 2026 at 3:04 am
Sub-Saharan Africa is running out of time and topsoil. A sweeping new meta-analysis synthesizing 317 peer-reviewed studies published between 2010 and 2025 has delivered the most comprehensive quantitative verdict yet on whether biologically derived inputs and engineered materials can rescue the region’s collapsing agricultural productivity. The answer, published in the journal Discover Agriculture, is a
- Antibody-Drug Combination Falls Short in First-Line PD-L1-High Metastatic Lung Cancer Trialby Bioengineer on September 13, 2026 at 3:02 am
A closely watched Phase 3 clinical trial has delivered a sobering verdict on one of the most anticipated treatment strategies in lung cancer medicine. Sacituzumab govitecan, an antibody-drug conjugate that has shown promise in several tumor types, failed to demonstrate a statistically significant improvement in progression-free survival when combined with the immunotherapy pembrolizumab as a
- New Diabetes Monitoring Pathway Keeps Older Cancer Patients Safe During Steroid Therapyby Bioengineer on September 13, 2026 at 3:02 am
Older adults undergoing cancer treatment face a hidden metabolic threat that has long slipped through the cracks of oncology care. Corticosteroids, which are woven into many chemotherapy regimens and supportive care protocols to suppress nausea, allergic reactions and immune-related toxicity, can send blood glucose soaring. For patients in their seventies and eighties, many of whom
- Cobalt-Based MOF Sensor Detects Anthrax Biomarker in Water in One Minuteby Bioengineer on September 13, 2026 at 3:00 am
A cobalt-based metal-organic framework that can flag the chemical fingerprint of anthrax spores in drinking water within a single minute has been developed by researchers seeking a faster, cheaper alternative to laboratory chromatography. The material, described in the journal Results in Chemistry, acts as a fluorescent probe that dims sharply in the presence of dipicolinic
- Environmental Fungus Corynascus verrucosus Turns Up in Dog Skin Infectionby Bioengineer on September 13, 2026 at 3:00 am
A fungal species better known for living quietly in soil and compost heaps has surfaced in an unexpected place: the inflamed skin of a family dog. In a case report published in Veterinary Medicine and Science, researchers at the University of Tehran describe what they believe is a rare recovery of Corynascus verrucosus, an environmental
- AI Predicts EV Charging Demand With 97.9% Accuracy From Real Grid Databy Bioengineer on September 13, 2026 at 2:57 am
Electric vehicles are quietly rewriting the rules of the power grid, and nowhere is that transformation more visible than along the highways that stitch countries together. In a new study published in Cluster Computing, researchers İlker Dursun and Aleyna Erkara of Sakarya University of Applied Sciences have demonstrated that a carefully engineered hybrid machine learning
- Scientists Build Solid Fat Analogue to Cut Saturated Fat in Emulsified Sausagesby Bioengineer on September 13, 2026 at 2:56 am
Processed meat products occupy a curious position in the modern food supply. They are among the most widely consumed protein foods in the world, yet they are also frequently criticized for their fat content, and in particular for the proportion of saturated fat contributed by animal fat. In emulsified sausages such as frankfurters, bolognas, and
- Shifting Identities: How Lung Cancer Cells Change Face to Outsmart Treatmentby Bioengineer on September 13, 2026 at 2:55 am
Small-cell lung cancer has long been one of oncology’s most punishing adversaries. It grows with astonishing speed, spreads early, and presents a treatment paradox that has frustrated clinicians for decades: at diagnosis, tumors melt away under platinum-based chemotherapy, yet relapse is nearly universal, and the disease that returns is almost always resistant. A new review
- Chemists Craft a One-Handed Molecule That Disarms a Cell-Death Proteinby Bioengineer on September 13, 2026 at 2:54 am
A single protein called BAX sits at the gateway between life and death for human cells. When tissues are injured, stressed, or deprived of oxygen, BAX springs into action, punching holes in the outer membrane of mitochondria and triggering the self-destruct program known as apoptosis. For two decades, researchers have dreamed of finding a drug
